Abstract:IntroductionWe developed an analytic strategy that correlates gene expression and clinical outcomes as a means to identify novel candidate oncogenes operative in breast cancer. This analysis, followed by functional characterization, resulted in the identification of Jumonji Domain Containing 6 (JMJD6) protein as a novel driver of oncogenic properties in breast cancer.MethodsThrough microarray informatics, Cox proportional hazards regression was used to analyze the correlation between gene expression and distant metastasis-free survival (DMFS) of patients in 14 independent breast cancer cohorts. JMJD6 emerged as a top candidate gene robustly associated with poor patient survival. Immunohistochemistry, siRNA-mediated silencing, and forced overexpression of JMJD6 in cell-based assays elucidated molecular mechanisms of JMJD6 action in breast cancer progression and shed light on the clinical breast cancer subtypes relevant to JMJD6 action.ResultsJMJD6 was expressed at highest levels in tumors associated with worse outcomes, including ER- and basal-like, Claudin-low, Her2-enriched, and ER+ Luminal B tumors. High nuclear JMJD6 protein was associated with ER negativity, advanced grade, and poor differentiation in tissue microarrays. Separation of ER+/LN- patients that received endocrine monotherapy indicated that JMJD6 is predictive of poor outcome in treatment-specific subgroups. In breast cancer cell lines, loss of JMJD6 consistently resulted in suppressed proliferation but not apoptosis, whereas forced stable overexpression increased growth. In addition, knockdown of JMJD6 in invasive cell lines, such as MDA-MB231, decreased motility and invasion, whereas overexpression in MCF-7 cells slightly promoted motility but did not confer invasive growth. Microarray analysis showed that the most significant transcriptional changes occurred in cell-proliferation genes and genes of the TGF-β tumor-suppressor pathway. High proliferation was characterized by constitutively high cyclin E protein levels. The inverse relation of JMJD6 expression with TGF-β2 could be extrapolated to the breast cancer cohorts, suggesting that JMJD6 may affect similar pathways in primary breast cancer.ConclusionsJMJD6 is a novel biomarker of tumor aggressiveness with functional implications in breast cancer growth and migration.

Jumonji Domain‐containing Protein 6 Protein and Its Role in Cancer

Jumonji domain-containing protein 6 protein and its role in cancer

JMJD5 Interacts with P53 and Negatively Regulates P53 Function in Control of Cell Cycle and Proliferation.

Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response

JMJD family proteins in cancer and inflammation

JMJD5 Inhibits Lung Cancer Progression by Facilitating EGFR Proteasomal Degradation

JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation.

A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo.

Jumonji Domain-Containing Protein 6 Functions As a Marker of Head and Neck Squamous Cell Carcinoma at Advanced Stage with No Effect on Prognosis

JMJD5 Inhibits Lung Cancer Progression by Regulating Glucose Metabolism Through the P53/tigar Pathway

JMJD6 Promotes Melanoma Carcinogenesis Through Regulation of the Alternative Splicing of PAK1, a Key MAPK Signaling Component

JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity

JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

Jumonji Domain-Containing 6 (JMJD6) Identified As a Potential Therapeutic Target in Ovarian Cancer

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3/IL-10 axis

Histone Demethylase JMJD2D: A Novel Player in Colorectal and Hepatocellular Cancers

Emerging role of Jumonji domain-containing protein D3 (JMJD3) in inflammatory diseases

Roles of Histone Demethylase JMJD3 in Tumorigenesis

Histone demethylase JMJD1Aand its biological functions

JMJD8 Is an M2 Macrophage Biomarker, and It Associates With DNA Damage Repair to Facilitate Stemness Maintenance, Chemoresistance, and Immunosuppression in Pan-Cancer